Latest California Healthline Stories
Watch: Rulings on Abortion Pill Have Far-Reaching Repercussions
Sarah Varney, a senior correspondent for KHN, joins Ali Rogin of PBS NewsHour to discuss the ruling by a federal judge in Texas that threatens nationwide access to the widely used abortion drug mifepristone, and a separate ruling in Washington state that reached the opposite conclusion.
Gov. Newsom Wanted California to Cut Ties With Walgreens. Then Federal Law Got in the Way.
Gov. Gavin Newsom declared that California would cut ties with Walgreens after the company said it would not distribute abortion pills in some states. But federal rules make it difficult for the state to unwind its Medicaid prescription drug agreement, which paid Walgreens $1.5 billion last year.
States Try to Obscure Execution Details as Drugmakers Hinder Lethal Injection
Pharmaceutical companies have put the brakes on many states’ ability to execute prisoners using lethal injections. Lacking alternatives, states are trying to keep the public from learning details about how they carry out executions.
Journalist Angela Hart Delves Into Insulin Costs and Medicaid Housing Support
California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Sen. Sanders Shows Fire, but Seeks Modest Goals, in His Debut Drug Hearing as Health Chair
The Vermont independent and former presidential candidate was all fire and brimstone at his first hearing on drug prices as head of the Senate HELP Committee. He also pursued a more modest goal of covid vaccine price reductions. It isn’t clear whether Sanders will succeed in even that, but he has put affordability front and center.
KFF Health News' 'What the Health?': The Policy, and Politics, of Medicare Advantage
Medicare Advantage, the private-sector alternative to original Medicare, now enrolls nearly half of all Medicare beneficiaries. But it remains controversial because — while most of its subscribers like the extra benefits many plans provide — the program frequently costs the federal government more than if those seniors remained in the fully public program. That controversy […]
Judge Signals He Could Rule to Halt Sales of Common Abortion Pill
A U.S. District Court case is being widely followed because the judge’s decision could overturn the FDA’s approval of mifepristone two decades ago. With abortion rights polling well even in red states, anti-abortion activists are increasingly turning to the courts to achieve their aims.
California eligió a la compañía de genéricos Civica para producir insulina de bajo costo
Civica está desarrollando tres tipos de insulina genérica, conocida como biosimilar, que estarán disponibles tanto en viales como en plumas inyectables, a un costo de entre $30 y $55.
California Picks Generic Drug Company Civica to Produce Low-Cost Insulin
Gov. Gavin Newsom, who blasted pharmaceutical companies for gouging Californians, is moving ahead with state-branded insulin. He’s also eyeing other generic drugs.
New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?
In November, the CDC released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.